Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves a new type of schizophrenia drug
FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel treatment for schizophrenia in decades.
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This drug takes the first new approach to schizophrenia treatment in decades,” the Food and Drug Administration said.
FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to schizophrenia treatment in decades,
C&EN
17h
FDA approves Cobenfy, a first-in-class schizophrenia drug
The US Food and
Drug
Administration has approved Cobenfy, also known as KarXT, a new
schizophrenia
treatment. The
drug
was developed by Karuna Therapeutics, which was bought by Bristol Myers ...
92.7 WMAY
2h
FDA approves first new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
16h
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday.
5h
FDA approves new kind of drug for schizophrenia
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
FDA
Cobenfy
Bristol Myers Squibb
Feedback